Abstract
Intracerebral hemorrhage (ICH) volume remains the most important predictor of long-term functional outcome and mortality.1,2 ICH growth frequently occurs within the first few hours after symptom onset and represents an attractive target for interventions with the aim to stop the bleeding, a current priority research goal in ICH.3 Pharmacological measures to prevent ICH growth and to improve long-term functional outcome in unselected patient populations with ICH associated with arterial hypertension have so far not proven successful.4,5 Therefore, patient selection for all future ICH treatment trials should focus on risk for ICH expansion and based on widely available tools not posing additional risks to patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
